NEW HAVEN, Conn. — BioCT, Connecticut’s life sciences trade organization, said it has appointed four senior industry leaders to its Board of Directors, expanding the organization’s leadership as it continues to support and grow the state’s bioscience ecosystem.
The newly elected board members are Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine and serial bioscience entrepreneur; Angela Cacace, PhD, Chief Scientific Officer at Arvinas; Jennifer Good, Co-Founder, President, and Chief Executive Officer of Trevi Therapeutics; and Sydney Klein, Chief Information Security Officer and Head of Enterprise IT at Bristol Myers Squibb.
BioCT said Dr. Cacace will succeed former board member John Houston, PhD, who announced in July 2025 that he plans to retire as President and Chief Executive Officer of Arvinas. Houston will continue his involvement with BioCT as a member of the organization’s Emeritus Board, which is composed of former board leaders who have made lasting contributions to BioCT’s mission.
“Our strength as an organization is driven in large part by the commitment of our Board,” said Jodie Gillon, President and Chief Executive Officer of BioCT. “They have supported and enabled me to drive forward ambitious strategies. I am confident that Ranjit, Angela, Jennifer, and Sydney are exceptional additions, bringing complementary perspectives from Big Pharma, startups, venture capital, and emerging technologies such as machine learning. Together, they strengthen BioCT’s role as the unified voice for Connecticut’s life sciences and for those looking to come, stay, and grow here.”
BioCT Board Co-Chairs David Scheer, President of Scheer and Company, and Stan Choy, bioscience entrepreneur, also welcomed the new members, saying the appointments come at an important moment as the organization and the broader industry navigate a changing environment.
Ranjit Bindra, MD, PhD, is a physician-scientist at Yale School of Medicine and Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. His laboratory discovered that certain IDH1/2-mutant tumors have a critical DNA repair vulnerability that makes them exceptionally sensitive to PARP inhibitors, a breakthrough now being tested in clinical trials to improve outcomes for cancer patients. He is also a serial bioscience entrepreneur, having co-founded CapeHaven, Modifi Bio, B3 Therapeutics, Alphina Therapeutics, Cybrexa Therapeutics, and Helix Therapeutics.
Angela Cacace, PhD, is Chief Scientific Officer at Arvinas and has spent three decades leading drug discovery in neuroscience and oncology. She has advanced the company’s PROTAC Discovery Engine, enabling novel approaches to effectively target neurologic diseases. Previously, she held leadership roles at Fulcrum Therapeutics, Bristol Myers Squibb, and Pfizer, where she grew scientific teams, advanced development candidates, and drove platform innovations.
Jennifer Good is Co-Founder, President, and Chief Executive Officer of Trevi Therapeutics, where she has led the company since its
founding in 2011. Trevi is a publicly traded biotechnology company preparing to advance its drug into Phase 3 development. She has also held senior executive roles in the biopharmaceutical industry, including President and Chief Executive Officer at Penwest Pharmaceuticals, and has served on the boards of Trevi, Rhythm Pharmaceuticals, and Juniper Pharmaceuticals prior to its acquisition by Catalent.
Sydney Klein is Chief Information Security Officer and Head of Enterprise IT at Bristol Myers Squibb. She brings more than two decades of technology and cybersecurity leadership experience and oversees the company’s global cybersecurity, infrastructure, cloud computing, data platforms, and digital workforce functions. She has played a key role in enterprise transformation and the responsible adoption of artificial intelligence, with a focus on secure, scalable digital solutions and data privacy.
